ベッドサイドで使える腫瘍循環器入門

出版社： 中外医学社
著者：
発行日： 2019-11-01
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784498134386
電子書籍版： 2019-11-01 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,960 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

がんと心血管疾患が合併した際にどちらを優先して治療するか．両疾患が複雑に絡み合ったケースに対して，腫瘍学あるいは循環器学単独の知識では時に太刀打ちできない．本書では，腫瘍循環器のエキスパートである筆者が，臨床現場での実践的知識を惜しげもなく披露している．はじめて腫瘍循環器に取り組む医師・メディカルスタッフにとって，最新の腫瘍循環器領域のスタンダードにキャッチアップするのに最適な一冊である．

目次

  • 総　論
    　Q1　腫瘍循環器外来とはなんですか？　またその意義はなんでしょうか？
    　Q2　腫瘍循環器外来を行うのに必要なリソースとうまく運営するコツはなんですか？
    　Q3　腫瘍循環器外来の検査ではどのような項目が重要でしょうか？
    　Q4　Type 1／Type 2の心毒性とはなんでしょうか？
    　Q5　がんサバイバーのフォローはどのように考えればよいでしょうか？

    製剤別各論
    　Q6　HER2阻害薬による心毒性のフォロー方法はどのようにすればよいでしょうか？
    　Q7　アントラサイクリン系による心毒性のフォロー方法は
    　　　　どのようにすればよいでしょうか？
    　Q8　免疫チェックポイント阻害薬による心血管障害のフォロー方法は
    　　　　どのようにすればよいでしょうか？
    　Q9　チロシンキナーゼ阻害薬による心血管障害のフォロー方法は
    　　　　どのようにすればよいでしょうか？
    　Q10　VEGF阻害薬による高血圧症のフォロー方法はどのようにすればよいでしょうか？

    症候別各論
    　Q11　心筋障害発生時の改善を期待して投与できる薬剤と，抗がん剤の中止・減量は
    　　　　どのように考えればよいでしょうか？
    　Q12　がんの患者さんの心房細動はどのようなことに注意してマネジメントすれば
    　　　　よいでしょうか？
    　Q13　放射線治療関連の冠動脈疾患で意識すべきなのはどのような点でしょうか？
    　Q14　がん関連動脈血栓塞栓症の診断・治療はどのようにすればよいでしょうか？
    　Q15　がん関連静脈血栓塞栓症のリスク評価はどのようにすればよいでしょうか？
    　Q16　がん関連静脈血栓塞栓症の急性期・遠隔期の診断と治療はどのようにすれば
    　　　　よいでしょうか？
    　Q17　がん患者さんの肺高血圧症はどのように診断・治療すればよいでしょうか？
    　Q18　PTTMとはどのような病態で診断・治療はどのようにすればよいでしょうか？
    　Q19　がん患者の心臓リハビリテーションはどのように考えますか？
    　Q20　がん患者さんの心囊液はどのタイミングでドレナージすればよいでしょうか？
    　  　
    付録　三田病院のフォロープロトコールとフローチャート一覧

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論

P.6 掲載の参考文献
(1) Patnaik JL, Byers T, DiGuiseppi C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer : a retrospective cohort study. Breast Cancer Res. 2011 ; 13 : R64.
PubMed
(2) Hayek SS, Ganatra S, Lenneman C, et al. Preparing the cardiovascular workforce to care for oncology patients : JACC review topic of the week. J Am Coll Cardiol. 2019 ; 73 : 2226-35.
 
P.12 掲載の参考文献
(1) Montazeri K, Unitt C, Foody JM, et al. ABCDE steps to prevent heart disease in breast cancer survivors. Circulation. 2014 ; 130 : e157-9.
PubMed
P.19 掲載の参考文献
(1) Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000 ; 342 : 1077-84.
PubMed
(2) Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 ; 35 : 893-911.
 
(3) Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 ; 37 : 2768-801.
 
(4) Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 ; 27 : 911-39.
PubMed
(5) Villarraga HR, Herrmann J. Nkomo VT. Cardio-oncology : role of echocardiography. Prog Cardiovasc Dis. 2014 ; 57 : 10-8.
PubMed
(6) Negishi K, Negishi T, Hare JL, et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013 ; 26 : 493-8.
PubMed
(7) Mousavi N, Tan TC, Ali M, et al. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging. 2015 ; 16 : 977-84.
PubMed
(8) Tang Q. Jiang Y, Xu Y, et al. Speckle tracking echocardiography predicts early subclinical anthracycline cardiotoxicity in patients with breast cancer. J Clin Ultrasound. 2017 ; 45 : 222-30.
PubMed
(9) Thavendiranathan P, Poulin F, Lim KD, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy : a systematic review. J Am Coll Cardiol. 2014 ; 63 : 2751-68.
PubMed
(10) Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000 ; 36 : 517-22.
PubMed
(11) Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004 ; 109 : 2749-54.
PubMed
(12) Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014 ; 63 : 809-16.
PubMed
(13) Herrmann J, Lerman A, Sandhu NP, et al. Evaluation and management of patients with heart disease and cancer : cardio-oncology. Mayo Clin Proc. 2014 ; 89 : 1287-306.
PubMed
P.24 掲載の参考文献
(1) Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 ; 37 : 2768-801.
 
(2) Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 ; 27 : 911-39.
PubMed
(3) Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 ; 131 : 1981-8.
PubMed
(4) Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity : clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010 ; 28 : 3910-6.
PubMed
(5) Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction : time to recognize a new entity. J Clin Oncol. 2005 ; 23 : 2900-2.
PubMed
P.29 掲載の参考文献
(1) Armstrong GT, Chen Y, Yasui Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016 ; 374 : 833-42.
PubMed
(2) Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer : a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009 ; 27 : 2328-38.
PubMed
(3) Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013 ; 31 : 3673-80.
PubMed
(4) Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer : a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015 ; 16 : e123-36.
PubMed
(5) van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012 ; 30 : 1429-37.
PubMed
(6) Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer : role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol. 2012 ; 30 : 1415-21.
 
(7) Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer : results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015 ; 65 : 2511-22.
PubMed
(8) Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity : the CECCY trial. J Am Coll Cardiol. 2018 ; 71 : 2281-90.
 
(9) Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 ; 35 : 893-911.
 

製剤別各論

P.40 掲載の参考文献
(1) Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med. 2001 : 7 : 548-52.
PubMed
(2) Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology/College of American Pathologists clinical practice guide-line update. J Clin Oncol. 2013 : 31 : 3997-4013.
 
(3) Kitani T, Ong SG, Lam CK, et al. Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer. Circulation. 2019 : 139 : 2451-65.
PubMed
(4) Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008 : 118 : 84-95.
PubMed
(5) Sawyer DB, Zuppinger C, Miller TA, et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1 beta and anti-erbB2 : potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002 : 105 : 1551-4.
PubMed
(6) Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012 ; : CD006243.
PubMed
(7) Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 ; 27 : 911-39.
PubMed
(8) Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 : 353 : 1659-72.
PubMed
(9) Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012 ; 30 : 3792-9.
PubMed
(10) Negishi K, Negishi T, Hare JL, et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013 ; 26 : 493-8.
PubMed
(11) Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA) : a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016 ; 37 : 1671-80.
 
(12) Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer : a randomized clinical trial. JAMA Oncol. 2016 ; 2 : 1030-7.
PubMed
P.49 掲載の参考文献
(1) Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity : basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc. 2014 ; 3 : e000665.
PubMed
(2) Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012 ; 18 : 1639-42.
PubMed
(3) Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998 ; 25 : 72-85.
 
(4) Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 ; 131 : 1981-8.
PubMed
(5) Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000 ; 342 : 1077-84.
PubMed
(6) Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin : a retrospective analysis of three trials. Cancer. 2003 ; 97 : 2869-79.
PubMed
(7) Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 ; 35 : 893-911.
 
(8) Mousavi N, Tan TC, Ali M, et al. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging. 2015 ; 16 : 977-84.
PubMed
(9) Wang L, Tan TC, Halpern EF, et al. Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy. Am J Cardiol. 2015 ; 116 : 442-6.
PubMed
(10) Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 ; 27 : 911-39.
PubMed
(11) Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004 ; 109 : 2749-54.
PubMed
(12) Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006 ; 114 : 2474-81.
PubMed
(13) Avila MS, Ayub-Ferreira Sm, de Barros Wanderley MR Jr, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity : the CECCY trial. J Am Coll Cardiol. 2018 ; 71 : 2281-90.
 
P.59 掲載の参考文献
(1) Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016 ; 375 : 1749-55.
PubMed
(2) Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors : an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018 ; 19 : 1579-89.
 
(3) Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the setting of cancer therapeutics. Circulation. 2019 ; 140 : 80-91.
PubMed
(4) Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018 ; 71 : 1755-64.
PubMed
P.66 掲載の参考文献
(1) Hall PS, Harshman LC, Srinivas S, et al. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013 ; 1 : 72-8.
PubMed
(2) Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 ; 19 : 9-42.
 
(3) Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of front-line nilotinib vs imatinib for chronic myeloid leukemia in chronic phase : 5-year update of the randomized ENESTnd trial. Leukemia. 2016 ; 30 : 1044-54.
 
(4) Abdel-Qadir H, Ethier JL, Lee DS, et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy : a systematic review and meta-analysis. Cancer Treat Rev. 2017 ; 53 : 120-7.
PubMed
(5) Dahlen T, Edgren G, Lambe M, et al ; Swedish CML Group and the Swedish CML Register Group. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia : a population-based cohort study. Ann Intern Med. 2016 ; 165 : 161-6.
PubMed
(6) Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 ; 369 : 1783-96.
 
(7) Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia : final 5-year results of the bhase 2 PACE trial. Blood. 2018 ; 132 : 393-404.
 
(8) Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dosse intensity of ponatinib on selected adverse events : multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016 ; 48 : 84-91.
 
(9) Douxfils J, Haguet H, Mullier F, et al. Association between BCR-ABL tyrosine kinaseinhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival : a systematic review and meta-analysis. JAMA Oncol. 2016 ; 2 : 625-32.
 
(10) Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015 ; 33 : 4210-8.
PubMed
P.73 掲載の参考文献
(1) Li W, Croce K, Steensma DP, et al. Vascular and metabolic implications of novel targeted cancer therapies : focus on kinase inhibitors. J Am Coll Cardiol. 2015 ; 66 : 1160-78.
PubMed
(2) Mayer EL, Dallabrida SM, Rupnick MA, et al. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011 ; 58 : 85-92.
PubMed
(3) Dhaun N, Webb DJ. Receptor tyrosine kinase inhibition, hypertension, and proteinuria : is endothelin the smoking gun? Hypertension. 2010 ; 56 : 575-7.
PubMed
(4) Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007 ; 96 : 1788-95.
PubMed
(5) Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011 ; 103 : 763-73.
PubMed
(6) Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer : a systematic review and meta-analysis. Lancet Oncol. 2008 ; 9 : 117-23.
 
(7) Pande A, Lombardo J, Spangenthal E, et al. Hypertension secondary to anti-angiogenic therapy : experience with bevacizumab. Anticancer Res. 2007 ; 27 : 3465-70.
PubMed
(8) McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 ; 21 : 2471-9.
PubMed
(9) Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy : incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009 ; 53 : 2231-47.
PubMed

症候別各論

P.82 掲載の参考文献
(1) Yancy CW, Jessup M, Bozkurt B, et al. ; Writing Committee Members. 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 ; 128 : e240-327.
 
(2) Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 ; 19 : 9-42.
 
(3) Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA) : a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016 ; 37 : 1671-80.
 
(4) Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity : the CECCY trial. J Am Coll Cardiol. 2018 ; 71 : 2281-90.
 
(5) Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006 ; 114 : 2474-81.
PubMed
(6) Cornell RF, Ky B, Weiss BM, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019 ; 37 : 1946-55.
PubMed
(7) Lopez-Fernandez T, Martin Garcia A, Santaballa Beltran A, et al. Cardio-onco-hematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol (Engl Ed). 2017 ; 70 : 474-86.
PubMed
(8) Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014 ; 15 : 1063-93.
PubMed
P.88 掲載の参考文献
(1) Hu YF, Liu CJ, Chang PM, et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol. 2013 ; 165 : 355-7.
PubMed
(2) Erichsen R, Christiansen CF, Mehnert F, et al. Colorectal cancer and risk of atrial fibrillation and flutter : a population-based case-control study. Intern Emerg Med. 2012 ; 7 : 431-8.
PubMed
(3) Guzzetti S, Costantino G, Vernocchi A, et al. First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation. Intern Emerg Med. 2008 ; 3 : 227-31
PubMed
(4) Onaitis M, D'Amico T, Zhao Y, et al. Risk factors for atrial fibrillation after lung cancer surgery : analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg. 2010 ; 90 : 368-74.
 
(5) Bhave PD, Goldman LE, Vittinghoff E, et al. Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery. Am Heart J. 2012 ; 164 : 918-24.
PubMed
(6) Onaitis M, D'Amico T, Zhao Y, et al. Risk factors for atrial fibrillation after lung cancer surgery : analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg. 2010 ; 90 : 368-74.
 
(7) Nojiri T, Maeda H, Takeuchi Y, et al. Predictive value of preoperative tissue Doppler echocardiographic analysis for postoperative atrial fibrillation after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2010 ; 140 : 764-8.
PubMed
(8) Nojiri T, Maeda H, Takeuchi Y, et al. Predictive value of B-type natriuretic peptide for postoperative atrial fibrillation following pulmonary resection for lung cancer. Eur J Cardiothorac Surg. 2010 ; 37 : 787-91.
PubMed
(9) Nojiri T, Yamamoto K, Maeda H, et al. Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer. Gen Thorac Cardiovasc Surg. 2011 ; 59 : 799-805.
 
(10) Riber LP, Christensen TD, Jensen HK, et al. Amiodarone significantly decreases atrial fibrillation in patients undergoing surgery for lung cancer. Ann Thorac Surg. 2012 ; 94 : 339-44 ; discussion 345-6.
 
(11) Bhave PD, Goldman LE, Vittinghoff E, et al. Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery. Am Heart J. 2012 ; 164 : 918-24.
PubMed
(12) Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology : atrial fibrillation in cancer. J Am Coll Cardiol. 2014 ; 63 : 945-53.
 
(13) Barber M, Nguyen LS, Wassermann J, et al. Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovasc Res. 2019 ; 115 : 878-94.
PubMed
(14) Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 ; 379 : 2517-28.
PubMed
(15) Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use : a systematic review and meta-analysis. Blood. 2016 ; 128 : 138-40.
PubMed
(16) Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017 ; 1 : 1739-48.
PubMed
(17) Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio : a retrospective analysis. J Clin Oncol. 2000 ; 18 : 3078-83.
PubMed
P.95 掲載の参考文献
(1) Bryant AK, Banegas MP, Martinez ME, et al. Trends in radiation therapy among cancer survivors in the United States, 2000-2030. Cancer Epidemiol Biomarkers Prev. 2017 ; 26 : 963-70.
PubMed
(2) Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults : a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2013 ; 26 : 1013-32.
PubMed
(3) Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol. 2011 ; 154 : 23-31.
PubMed
(4) van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment : 40-year disease risk. JAMA Intern Med. 2015 ; 175 : 1007-17.
PubMed
(5) McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011 ; 100 : 167-75.
PubMed
(6) Sardar P, Kundu A, Chatterjee S, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer : a systematic review and meta-analysis. Clin Cardiol. 2017 ; 40 : 73-81.
PubMed
(7) Groarke JD, Tanguturi VK, Hainer J, et al. Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation : evidence of cardiac autonomic dysfunction and impact on outcomes. J Am Coll Cardiol. 2015 ; 65 : 573-83.
PubMed
(8) Nilsson G, Holmberg L, Garmo H, et al. Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol. 2012 ; 30 : 380-6.
PubMed
(9) Campen CJ, Kranick SM, Kasner SE, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke. 2012 ; 43 : 3035-40.
PubMed
(10) Reed GW, Masri A, Griffin BP, et al. Long-term mortality in patients with radiation-associated coronary artery disease treated with percutaneous coronary intervention. Circ Cardiovasc Interv. 2016 ; 9. pii : e003483.
 
(11) Fender EA, Liang JJ, Sio TT, et al. Percutaneous revascularization in patients treated with thoracic radiation for cancer. Am Heart J. 2017 ; 187 : 98-103.
PubMed
(12) Wu W, Masri A, Popovic ZB, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery : a cohort study. Circulation. 2013 : 127 : 1476-85.
PubMed
(13) Sio TT, Liang JJ, Chang K, et al. Dosimetric correlate of cardiac-specific survival among patients undergoing coronary artery stenting after thoracic radiotherapy for cancer. Am J Clin Oncol. 2017 ; 40 : 133-9.
PubMed
(14) Liang JJ, Sio TT, Slusser JP, et al. Outcomes after percutaneous coronary intervention with stents in patients treated with thoracic external beam radiation for cancer. JACC Cardiovasc Interv. 2014 ; 7 : 1412-20.
PubMed
(15) Desai MY, Windecker S, Lancellotti P, et al. Prevention, diagnosis, and management of radiation-associated cardiac disease : JACC scientific expert panel. J Am Coll Cardiol. 2019 ; 74 : 905-27.
 
(16) Drost L, Yee C, Lam H, et al. A systematic review of heart dose in breast radiotherapy. Clin Breast Cancer. 2018 ; 18 : e819-e824.
 
P.105 掲載の参考文献
(1) Campia U, Moslehi JJ, Amiri-Kordestani L, et al. Cardio-oncology : vascular and metabolic perspectives : a scientific statement from the american Heart Association. Circulation. 2019 ; 139 : e579-e602.
PubMed
(2) Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 ; 37 : 2768-801.
 
(3) Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults : a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013 ; 14 : 721-40.
PubMed
(4) Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 ; 356 : 1503-16.
 
(5) el-Shami K, Griffiths E, Streiff M. Nonbacterial thrombotic endocarditis in cancer patients : pathogenesis, diagnosis, and treatment. Oncologist. 2007 ; 12 : 518-23.
PubMed
(6) Markides V, Nihoyannopoulos P. Non-bacterial thrombotic endocarditis. Eur J Echocardiogr. 2000 ; 1 : 291-4.
PubMed
P.113 掲載の参考文献
(1) Sorensen HT. Mellemkjaer L. Olsen JH. et a l. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000 ; 343 : 1846-50.
 
(2) Nakamura M, Miyata T, Ozeki Y, et al. Current venous thromboembolism management and outcomes in Japan. Circ J. 2014 ; 78 : 708-17.
PubMed
(3) Khorana AA, Liebman HA, White RH, et al. The risk of venous thromboembolism in patients with cancer. In : ASCO Educational Book. Alexandria : American Society of Clinical Oncology ; 2008. p. 240-8.
 
(4) Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer : a systematic review and meta-analysis. PLoS Med. 2012 ; 9 : e1001275.
 
(5) Ay C. Pabinger I, Cohen AT. Cancer-associated venous thromboembolism : Burden, mechanisms, and management. Thromb Haemost. 2017 ; 117 : 219-30.
PubMed
(6) Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 ; 111 : 4902-7.
PubMed
(7) Trujillo-Santos J, Di Micco P, Iannuzzo M, et al. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008 ; 100 : 905-11.
PubMed
(8) Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients : validation of a thrombosis risk score. J Thromb Haemost. 2004 ; 2 : 2156-61.
PubMed
(9) Khorana AA, Francis CW, Culakova E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005 ; 104 : 2822-9.
 
(10) Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010 ; 116 : 5377-82.
PubMed
(11) Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients : results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008 ; 112 : 2703-8.
PubMed
(12) Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013 ; 122 : 2011-8.
PubMed
(13) Li W, Croce K, Steensma DP, et al. Vascular and metabolic implications of novel targeted cancer therapies : focus on kinase inhibitors. J Am Coll Cardiol. 2015 : 66 : 1160-78.
PubMed
(14) Gottlied RA, Mehta PK, Cardio-Oncology : principles. prevention and management. Academic press : 2017.
 
(15) Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide : implications for therapy. Blood. 2002 ; 100 : 1168-71
 
(16) Li W, Garcia D, Cornell RF, et a l. Cardiovascular and thrombotic complications of novel multiple myeloma therapies : a review. JAMA Oncol. 2017 ; 3 : 980-8.
 
P.124 掲載の参考文献
(1) Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 ; 349 : 146-53.
PubMed
(2) Posch F, Konigsbrugge O, Zielinski C, et al. Treatment of venous thromboem-bolism in patients with cancer : a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015 : 136 : 582-9.
 
(3) Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005 ; 23 : 2123-9.
PubMed
(4) Dearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease : CHEST Guideline and Expert Panel Report. Chest. 2016 ; 149 : 315-52.
 
(5) Lyman GH, Bohlke K, Falanga A, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer : American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015 ; 11 : e442-4.
 
(6) Mandala M, Labianca R ; European Society for Medical Oncology. Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management. Thromb Res. 2010 : 125 Suppl 2 : S117-9.
 
(7) Farge D, Debourdeau P, Beckers M, et al. International clinical practice guide-lines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013 ; 11 : 56-70.
 
(8) Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002 ; 100 : 3484-8.
PubMed
(9) Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months : the DALTECAN Study. J Thromb Haemost. 2015 ; 13 : 1028-35.
PubMed
(10) Raslob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 ; 378 : 615-24.
PubMed
(11) Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism : results of a randomized trial (SELECT-D). J Clin Oncol. 2018 ; 36 : 2017-23.
 
(12) 田村雄一, 北方博規, 笹口浩久, 他. シングルドラッグアプローチも含む本邦における. リバーロキサバンによる急性肺塞栓症の治療経験. Prog Med. 2016 ; 36 : 817-26.
 
(13) Konstantinides SV, Torbickc A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 ; 35 : 3033-69. 3069a-3069k.
 
(14) Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to Prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019 ; 380 : 711-9.
PubMed
P.136 掲載の参考文献
(1) Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012 ; 125 : 2128-37.
PubMed
(2) Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest. 2005 ; 115 : 2691-4.
PubMed
(3) Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension : results of the randomized IMPRE5 study. Circulation. 2013 ; 127 : 1128-38.
 
(4) Guignabert C, Phan, C Seferian A, etal. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016 ; 126 : 3207-18.
PubMed
(5) Perros F, Gunther S, Ranchoux B, et al. Mitomycin-induced pulmonary venoocclusive disease : evidence from human disease and animal models. Circulation. 2015 ; 132 : 834-47.
PubMed
(6) Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 ; 53. pii : 1801913.
 
(7) Pulido T, Adzerilkhol, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 ; 369 : 809-18.
PubMed
(8) Steensma DP, HooK CC, Stafford SL, et al. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002 ; 118 : 813-6.
PubMed
(9) Weinschenker P, Kutner JM, Salvajoli JV, et al. Whole-pulmonary low-dose radiation therapy in agnogenic myeloid metaplasia with diffuse lung involvement. Am J Hematol. 2002 ; 69 : 277-80.
PubMed
(10) Holcomb BW Jr, Loyd JE, Ely EW, et al. Pulmonary veno-occlusive disease : a case series and new observations. Chest. 2000 ; 118 : 1671-9.
PubMed
(11) Limsuwan A, Pakakasama S, Hongeng S. Reversible course of pulmonary arterial hypertension related to bone marrow transplantation. Heart Vessels. 2011 ; 26 : 557-61
 
(12) Steward CG, Pellier I. Mahajan A, et al. Severe pulmonary hypertension : a frequent complication of stem cell transplantation for malignant infantile osteopetrosis. Br J Haematol. 2004 ; 124 : 63-71.
PubMed
P.142 掲載の参考文献
(1) von Herbay A, Illes A, Waldherr R, et al. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer. 1990 ; 66 : 587-92.
PubMed
(2) Sato Y, Marutsuka K, Asada Y, et al. Pulmonary tumor thrombotic microangiopathy. Pathol Int. 1995 ; 45 : 436-40.
PubMed
(3) Miyano S, Izumi S, Takeda Y, et al. Pulmonary tumor thrombotic microangiopathy. J Clin Oncol. 2007 ; 25 : 597-9.
PubMed
(4) Ogawa A, Yamadori I, Matsubara O, et al. Pulmonary tumor thrombotic microangiopathy with circulatory failure treated with imatinib. Intern Med. 2013 ; 52 : 1927-30.
PubMed
P.148 掲載の参考文献
(1) Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014 ; 120 : 1290-314.
PubMed
(2) Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007 ; 99 : 365-75.
PubMed
(3) Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors : a scientific statement from the American Heart Association. Circulation. 2019 ; 139 : e997-e1012.
PubMed
(4) Ishikawa A, Otaka Y, Kamisako M, et al. Factors affecting lower limb muscle strength and cardiopulmonary fitness after allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2019 ; 27 : 1793-800.
PubMed
(5) Jones LW, Courneya KS, Mackey JR, et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol. 2012 ; 30 : 2530-7.
PubMed
(6) Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 ; 35 : 893-911.
 
P.154 掲載の参考文献
(1) Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol. 2005 ; 23 : 5211-6.
PubMed
(2) Jung HO. Pericardial effusion and pericardiocentesis : role of echocardiography. Korean Circ J. 2012 ; 42 : 725-34.
PubMed
(3) Tsang TS, Seward JB, Barnes ME, et al. Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. Mayo Clin Proc. 2000 ; 75 : 248-53.
PubMed
(4) Kunitoh H, Tamura T, Shibata T, et al. A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer. 2009 ; 100 : 464-9.
 
(5) Kaira K, Takise A, Kobayashi G, et al. Management of malignant pericardial effusion with instillation of mitomycin C in non-small cell lung cancer. Jpn J Clin Oncol. 2005 ; 35 : 57-60.
PubMed
(6) Imamura T, Tamura K, Takenaga M, et al. Intrapericardial OK-432 instillation for the management of malignant pericardial effusion. Cancer. 1991 ; 68 : 259-63.
PubMed

書評

最近チェックした商品履歴

Loading...